Advertisement

Exelixis, BMS collaborate on late-stage combination trial in first-line RCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Exelixis Inc. and Bristol-Myers Squibb Co. entered into a clinical development collaboration to evaluate Cabometyx (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with BMS’s Opdivo (nivolumab), either alone or in combination with Yervoy (ipilimumab).

The clinical development program, which will be co-funded by the companies, is expected to include a phase III pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma, and potentially other tumor types.

Cabometyx and Opdivo have both received approval in the U.S, and E.U. for specific uses in previously treated renal cell carcinoma, and both compounds are the subject of ongoing, global phase III pivotal trials in hepatocellular carcinoma. Opdivo is approved in the United States for previously treated bladder cancer.

Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement